DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)

China · Delayed Price · Currency is CNY

16.50

+0.25 (1.54%)

May 29, 2026, 3:00 PM CST

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Retail	22.35B	21.91B	20.49B	19.24B	15.28B
Retail Growth	2.02%	6.89%	6.50%	25.89%	10.99%
Franchise and Distribution	4.48B	3.94B	3.42B	1.54B	1.01B
Franchise and Distribution Growth	13.58%	15.12%	122.46%	52.79%	105.29%
Other Operations	635.01M	616.51M	589.44M	444.11M	446.56M
Other Operations Growth	3.00%	4.59%	32.72%	-0.55%	46.43%
Total	27.46B	26.46B	24.51B	21.22B	16.74B
Total Growth	3.77%	7.99%	15.46%	26.80%	14.90%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
China	27.50B	26.50B	24.53B	21.25B	16.76B
China Growth	3.80%	8.01%	15.45%	26.78%	14.92%
Total	27.50B	26.50B	24.53B	21.25B	16.76B
Total Growth	3.80%	8.01%	15.45%	26.78%	14.92%

Source: S&P Global Market Intelligence.